Speaker
Description
Dr Andrew Burgoyne received his Bachelor of Science (2009) with a double major in Chemistry and Biochemistry, Bachelor of Science Honours degree (2010) and Master of Science (2012) in Chemistry (cum laude) from the University of Johannesburg, South Africa, and his Ph.D. (2015) in Chemistry from the University of Cape Town, South Africa.
After a stint as a postdoctoral research fellow at the College of Pharmacy at the University of Hawaii at Hilo, Dr Burgoyne joined the Belgian Nuclear Research Centre SCK CEN to develop new radiopharmaceuticals harnessing therapeutic radioisotopes. While there he established new radioisotope production capabilities and developed radiochemical processing technologies to purify reactor produced radioisotopes.
Andrew then joined Oak Ridge National Laboratory to expand his portfolio and gain more experience in actinide chemistry. He is a R&D Staff Member Radiochemist in the Medical Isotopes Development Group, within the Radioisotope Science and Technology Division of the Isotope Science and Engineering Directorate, and now manages radioisotope production efforts for the US Department of Energy Isotope Program. Dr Burgoyne is the principal investigator for the R&D and production efforts of accelerator-produced actinium-225 (cGMP) from thorum-232, also for the fabrication of radium-224/lead-212 generators from thorium-228, and for tungsten-188/rhenium-188 production.
